Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of CD19 Chimeric Antigen Receptor (CAR) T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies

NCT04943016 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT04943016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04943016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of CD19 Chimeric Antigen Receptor (CAR) T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies
Lead sponsor
National Taiwan University Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
July 1, 2021
Completion date
December 31, 2024
Enrollment
12 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory b-cell malignancies